EP1545608A4 - Mammalian ch1 deleted mimetibodies, compositions, methods and uses - Google Patents

Mammalian ch1 deleted mimetibodies, compositions, methods and uses

Info

Publication number
EP1545608A4
EP1545608A4 EP03742272A EP03742272A EP1545608A4 EP 1545608 A4 EP1545608 A4 EP 1545608A4 EP 03742272 A EP03742272 A EP 03742272A EP 03742272 A EP03742272 A EP 03742272A EP 1545608 A4 EP1545608 A4 EP 1545608A4
Authority
EP
European Patent Office
Prior art keywords
mammalian
compositions
methods
deleted mimetibodies
mimetibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03742272A
Other languages
German (de)
French (fr)
Other versions
EP1545608A2 (en
Inventor
George A Heavner
David M Knight
John Ghrayeb
Bernard J Scallon
Thomas C Nesspor
Karen A Kutoloski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Original Assignee
Centocor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor Inc filed Critical Centocor Inc
Publication of EP1545608A2 publication Critical patent/EP1545608A2/en
Publication of EP1545608A4 publication Critical patent/EP1545608A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP03742272A 2002-06-28 2003-06-27 Mammalian ch1 deleted mimetibodies, compositions, methods and uses Withdrawn EP1545608A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39243102P 2002-06-28 2002-06-28
US392431P 2002-06-28
PCT/US2003/020347 WO2004002417A2 (en) 2002-06-28 2003-06-27 Mammalian ch1 deleted mimetibodies, compositions, methods and uses

Publications (2)

Publication Number Publication Date
EP1545608A2 EP1545608A2 (en) 2005-06-29
EP1545608A4 true EP1545608A4 (en) 2006-09-13

Family

ID=30000868

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03742272A Withdrawn EP1545608A4 (en) 2002-06-28 2003-06-27 Mammalian ch1 deleted mimetibodies, compositions, methods and uses

Country Status (6)

Country Link
EP (1) EP1545608A4 (en)
JP (1) JP2006504406A (en)
CN (1) CN1735433A (en)
AU (1) AU2003280130B2 (en)
CA (1) CA2490409A1 (en)
WO (1) WO2004002417A2 (en)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
MEP42108A (en) 1998-10-23 2011-02-10 Kiren Amgen Inc Dimeric thrombopoietin peptide mimetics binding to mp1 receptor and having thrombopoietic activity
WO2003084477A2 (en) * 2002-03-29 2003-10-16 Centocor, Inc. Mammalian cdr mimetibodies, compositions, methods and uses
US7241733B2 (en) * 2002-06-28 2007-07-10 Centocor, Inc. Mammalian EPO mimetic CH1 deleted mimetibodies, compositions, methods and uses
UA89481C2 (en) * 2003-09-30 2010-02-10 Центокор, Инк. Human epo mimetic hinge core mimetibodies, compositions, methods and uses
EP1687452A4 (en) * 2003-09-30 2008-08-06 Centocor Inc Human hinge core mimetibodies, compositions, methods and uses
CA2563379A1 (en) * 2004-03-31 2005-10-20 Centocor, Inc. Human glp-1 mimetibodies, compositions, methods and uses
EP1797127B1 (en) 2004-09-24 2017-06-14 Amgen Inc. Modified fc molecules
US20060084145A1 (en) * 2004-09-27 2006-04-20 Anderson Glenn M sRAGE mimetibody, compositions, methods and uses
ME01234B (en) * 2004-10-25 2013-06-20 Centocor Inc Melanocortin receptor binding mimetibodies, compositions, methods and uses
BRPI0520168A2 (en) * 2005-03-28 2009-04-22 Centocor Inc human glp-1 mimetibodies, compositions, methods and uses
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
US20100034819A1 (en) * 2006-03-31 2010-02-11 Centocor Inc. Human epo mimetic hinge core mimetibodies, compositions, methods and uses for preventing or treating glucose intolerance related conditions on renal disease associated anemia
US7943310B2 (en) 2006-08-30 2011-05-17 Centocor Ortho Biotech Inc. Methods for assessing response to therapy in subjects having ulcerative colitis
US8278415B2 (en) 2006-12-21 2012-10-02 Centocor, Inc. Dimeric high affinity EGFR constructs and uses thereof
US8834920B2 (en) 2006-12-21 2014-09-16 Alza Corporation Liposome composition for targeting egfr receptor
WO2008079973A2 (en) 2006-12-21 2008-07-03 Centocor, Inc. Egfr binding peptides and uses thereof
WO2008092209A1 (en) * 2007-02-01 2008-08-07 Arana Therapeutics Limited Protein construct with improved properties
EP2205280B1 (en) 2007-09-27 2019-09-04 Amgen Inc. Pharmaceutical formulations
EP2219602A1 (en) 2007-11-15 2010-08-25 Amgen, Inc Aqueous formulation of erythropoiesis stimulating protein stablised by antioxidants for parenteral administration
US9175078B2 (en) 2008-01-25 2015-11-03 Amgen Inc. Ferroportin antibodies and methods of use
AU2009246946B2 (en) 2008-05-01 2013-09-26 Amgen Inc. Anti-hepcidin antibodies and methods of use
JP5586607B2 (en) 2008-08-29 2014-09-10 ヤンセン バイオテツク，インコーポレーテツド Markers and methods for evaluating and treating ulcerative colitis and related diseases using a 20 gene panel
US20120052066A1 (en) 2008-11-07 2012-03-01 Cesar Calderon Markers and methods for assessing and treating lupus patients susceptible to photoprovocation
JP6018753B2 (en) 2008-11-13 2016-11-02 ザ・ジェネラル・ホスピタル・コーポレイションＴｈｅ Ｇｅｎｅｒａｌ Ｈｏｓｐｉｔａｌ Ｃｏｒｐｏｒａｔｉｏｎ Methods and compositions for controlling iron homeostasis by modulation of BMP-6
US9662271B2 (en) 2009-10-23 2017-05-30 Amgen Inc. Vial adapter and system
AU2010322205B2 (en) 2009-11-17 2015-01-22 Janssen Biotech, Inc. Improved bacterial membrane protein secretion
ES2581571T3 (en) 2009-11-17 2016-09-06 Janssen Biotech, Inc. Presentation of dimeric proteins of disulfide linked in filamentous phages
EP2536435B1 (en) 2010-02-18 2017-11-15 Janssen Biotech, Inc. Monkey homolog of human interferon omega
JP5908888B2 (en) 2010-04-16 2016-04-26 ヤンセン バイオテツク，インコーポレーテツド Modified plant cysteine protease and use thereof
EA032537B1 (en) 2010-06-07 2019-06-28 Эмджен Инк. Method of operation of a drug delivery device
EP2621950A4 (en) 2010-09-27 2015-09-02 Janssen Biotech Inc Antibodies binding human collagen ii
MX341790B (en) 2011-03-31 2016-09-02 Amgen Inc Vial adapter and system.
JP6038884B2 (en) 2011-04-20 2016-12-07 アムゲン・インコーポレーテッド Automatic injection device
LT3045189T (en) 2011-10-14 2018-06-25 Amgen Inc. Injector and method of assembly
EP4234694A3 (en) 2012-11-21 2023-09-06 Amgen Inc. Drug delivery device
JP6768501B2 (en) 2013-03-15 2020-10-14 アムゲン・インコーポレーテッド Drug cassettes, automatic injection machines, and automatic injection machine systems
US20150017162A1 (en) * 2013-03-15 2015-01-15 Omeros Corporation Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same
NZ631098A (en) 2013-03-15 2016-09-30 Intrinsic Lifesciences Llc Anti-hepcidin antibodies and uses thereof
JP6336564B2 (en) 2013-03-15 2018-06-06 アムゲン・インコーポレーテッド Drug cassette, auto-injector, and auto-injector system
AU2014238267B2 (en) 2013-03-22 2019-08-15 Amgen Inc. Injector and method of assembly
KR102458637B1 (en) 2013-10-24 2022-10-24 암겐 인코포레이티드 Injector and method of assembly
JP7051293B2 (en) 2013-10-24 2022-04-11 アムジエン・インコーポレーテツド Drug delivery system with temperature sensing control
US10994112B2 (en) 2014-02-05 2021-05-04 Amgen Inc. Drug delivery system with electromagnetic field generator
CA3193070A1 (en) 2014-05-07 2015-11-12 Amgen Inc. Autoinjector with shock reducing elements
SG11201609963PA (en) 2014-06-03 2016-12-29 Amgen Inc Devices and methods for assisting a user of a drug delivery device
CA2961917A1 (en) 2014-09-22 2016-03-31 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
US10695506B2 (en) 2014-10-14 2020-06-30 Amgen Inc. Drug injection device with visual and audio indicators
JP2017538512A (en) 2014-12-19 2017-12-28 アムジエン・インコーポレーテツド Drug delivery device including live button or user interface field
US10799630B2 (en) 2014-12-19 2020-10-13 Amgen Inc. Drug delivery device with proximity sensor
MX2017010466A (en) 2015-02-17 2018-06-06 Amgen Inc Drug delivery device with vacuum assisted securement and/or feedback.
EP3981450A1 (en) 2015-02-27 2022-04-13 Amgen, Inc Drug delivery device having a needle guard mechanism with a tunable threshold of resistance to needle guard movement
WO2017039786A1 (en) 2015-09-02 2017-03-09 Amgen Inc. Syringe assembly adapter for a syringe
JP7082568B2 (en) 2015-12-09 2022-06-08 アムジエン・インコーポレーテツド Automatic syringe with signal transduction cap
WO2017120178A1 (en) 2016-01-06 2017-07-13 Amgen Inc. Auto-injector with signaling electronics
ES2814287T3 (en) 2016-03-15 2021-03-26 Amgen Inc Reduce the likelihood of glass breakage in drug delivery devices
WO2017189089A1 (en) 2016-04-29 2017-11-02 Amgen Inc. Drug delivery device with messaging label
WO2017192287A1 (en) 2016-05-02 2017-11-09 Amgen Inc. Syringe adapter and guide for filling an on-body injector
ES2959783T3 (en) 2016-05-13 2024-02-28 Amgen Inc Vial Protective Cover Assembly
EP3458988B1 (en) 2016-05-16 2023-10-18 Amgen Inc. Data encryption in medical devices with limited computational capability
EP3465124A1 (en) 2016-06-03 2019-04-10 Amgen Inc. Impact testing apparatuses and methods for drug delivery devices
WO2018004842A1 (en) 2016-07-01 2018-01-04 Amgen Inc. Drug delivery device having minimized risk of component fracture upon impact events
US20190328965A1 (en) 2016-08-17 2019-10-31 Amgen Inc. Drug delivery device with placement detection
WO2018081234A1 (en) 2016-10-25 2018-05-03 Amgen Inc. On-body injector
CA3049780A1 (en) 2017-01-17 2018-07-26 Amgen Inc. Injection devices and related methods of use and assembly
JP7280189B2 (en) 2017-02-17 2023-05-23 アムジエン・インコーポレーテツド Insertion mechanism for drug delivery device
JP7064501B2 (en) 2017-02-17 2022-05-10 アムジエン・インコーポレーテツド Drug delivery device with sterile fluid flow path and related assembly methods
EP3592403A1 (en) 2017-03-06 2020-01-15 Amgen Inc. Drug delivery device with activation prevention feature
CA3052482A1 (en) 2017-03-07 2018-09-13 Amgen Inc. Needle insertion by overpressure
IL268386B2 (en) 2017-03-09 2023-11-01 Amgen Inc Insertion mechanism for drug delivery device
WO2018172219A1 (en) 2017-03-20 2018-09-27 F. Hoffmann-La Roche Ag Method for in vitro glycoengineering of an erythropoiesis stimulating protein
CN114588404A (en) 2017-03-28 2022-06-07 美国安进公司 Plunger rod and syringe assembly systems and methods
US11590294B2 (en) 2017-06-08 2023-02-28 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
EP3634546A1 (en) 2017-06-08 2020-04-15 Amgen Inc. Torque driven drug delivery device
JP7195276B2 (en) 2017-06-22 2022-12-23 アムジエン・インコーポレーテツド Collision/shock reduction due to device activation
WO2018237225A1 (en) 2017-06-23 2018-12-27 Amgen Inc. Electronic drug delivery device comprising a cap activated by a switch assembly
JP7408398B2 (en) 2017-07-14 2024-01-05 アムジエン・インコーポレーテツド Needle insertion and retraction system with dual torsion spring system
WO2019018169A1 (en) 2017-07-21 2019-01-24 Amgen Inc. Gas permeable sealing member for drug container and methods of assembly
US11484648B2 (en) 2017-07-25 2022-11-01 Amgen Inc. Drug delivery device with container access system and related method of assembly
EP3658203B1 (en) 2017-07-25 2022-08-31 Amgen Inc. Drug delivery device with gear module and related method of assembly
WO2019032482A2 (en) 2017-08-09 2019-02-14 Amgen Inc. Hydraulic-pneumatic pressurized chamber drug delivery system
US11077246B2 (en) 2017-08-18 2021-08-03 Amgen Inc. Wearable injector with sterile adhesive patch
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
WO2019070472A1 (en) 2017-10-04 2019-04-11 Amgen Inc. Flow adapter for drug delivery device
EP4257164A3 (en) 2017-10-06 2024-01-17 Amgen Inc. Drug delivery device with interlock assembly and related method of assembly
EP3694578A1 (en) 2017-10-09 2020-08-19 Amgen Inc. Drug delivery device with drive assembly and related method of assembly
WO2019090086A1 (en) 2017-11-03 2019-05-09 Amgen Inc. Systems and approaches for sterilizing a drug delivery device
MA50569A (en) 2017-11-06 2020-09-16 Amgen Inc FILLING-FINISHING UNITS AND ASSOCIATED PROCESSES
JP2021501616A (en) 2017-11-06 2021-01-21 アムジエン・インコーポレーテツド Drug delivery device with placement and flow detection
US11191904B2 (en) 2017-11-10 2021-12-07 Amgen Inc. Plungers for drug delivery devices
MA50904A (en) 2017-11-16 2020-09-23 Amgen Inc NEEDLE INSERTION MECHANISM FOR DRUG DELIVERY DEVICE
MA50903A (en) 2017-11-16 2021-05-12 Amgen Inc SELF-INJECTOR WITH STALL AND END POINT DETECTION
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
US20210260279A1 (en) 2018-07-24 2021-08-26 Amgen Inc. Hybrid drug delivery devices with optional grip portion and related method of preparation
EP3826699A1 (en) 2018-07-24 2021-06-02 Amgen Inc. Delivery devices for administering drugs
WO2020023444A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Delivery devices for administering drugs
WO2020023336A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with grip portion
EP3829692A1 (en) 2018-07-31 2021-06-09 Amgen Inc. Fluid path assembly for a drug delivery device
MA53724A (en) 2018-09-24 2021-12-29 Amgen Inc INTERVENTIONAL DOSING SYSTEMS AND METHODS
CA3110371A1 (en) 2018-09-28 2020-04-02 Amgen Inc. Muscle wire escapement activation assembly for a drug delivery device
CA3110529A1 (en) 2018-10-02 2020-04-09 Amgen Inc. Injection systems for drug delivery with internal force transmission
WO2020072846A1 (en) 2018-10-05 2020-04-09 Amgen Inc. Drug delivery device having dose indicator
EA202191037A1 (en) 2018-10-15 2021-08-05 Эмджен Инк. A DRUG DELIVERY DEVICE WITH A DAMPER MECHANISM
AR116703A1 (en) 2018-10-15 2021-06-02 Amgen Inc PLATFORM ASSEMBLY PROCESS FOR A DRUG MANAGEMENT DEVICE
MA54048A (en) 2018-11-01 2022-02-09 Amgen Inc DRUG DELIVERY DEVICES WITH PARTIAL RETRACTION OF DRUG DELIVERY BODY
TWI831847B (en) 2018-11-01 2024-02-11 美商安進公司 Drug delivery devices with partial needle retraction and methods for operating the same
MA54057A (en) 2018-11-01 2022-02-09 Amgen Inc DRUG DELIVERY ELEMENT PARTIAL RETRACTION DRUG DELIVERY DEVICES
JP2022529319A (en) 2019-04-24 2022-06-21 アムジエン・インコーポレーテツド Syringe sterility confirmation assembly and method
EP4017560A2 (en) 2019-08-23 2022-06-29 Amgen, Inc Drug delivery device with configurable needle shield engagement components and related methods
BR112023024278A2 (en) 2021-05-21 2024-01-30 Amgen Inc METHOD OF OPTIMIZING A FILLING RECIPE FOR A DRUG CONTAINER

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5608035A (en) * 1994-02-02 1997-03-04 Affymax Technologies N.V. Peptides and compounds that bind to the IL-1 receptor
WO2000024782A2 (en) * 1998-10-23 2000-05-04 Amgen Inc. Modified peptides, comprising an fc domain, as therapeutic agents
US20020012989A1 (en) * 1993-02-01 2002-01-31 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
WO2002046238A2 (en) * 2000-12-05 2002-06-13 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
WO2002046227A2 (en) * 2000-12-07 2002-06-13 Eli Lilly And Company Glp-1 fusion proteins
WO2003084477A2 (en) * 2002-03-29 2003-10-16 Centocor, Inc. Mammalian cdr mimetibodies, compositions, methods and uses

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4309989A (en) 1976-02-09 1982-01-12 The Curators Of The University Of Missouri Topical application of medication by ultrasound with coupling agent
FR2374910A1 (en) 1976-10-23 1978-07-21 Choay Sa PREPARATION BASED ON HEPARIN, INCLUDING LIPOSOMES, PROCESS FOR OBTAINING IT AND MEDICINAL PRODUCTS CONTAINING SUCH PREPARATIONS
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US5149636A (en) 1982-03-15 1992-09-22 Trustees Of Columbia University In The City Of New York Method for introducing cloned, amplifiable genes into eucaryotic cells and for producing proteinaceous products
US5169762A (en) 1983-03-03 1992-12-08 Genentech, Inc. Human nerve growth factor by recombinant technology
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
SE448277B (en) 1985-04-12 1987-02-09 Draco Ab INDICATOR DEVICE WITH A DOSAGE DEVICE FOR MEDICINAL PRODUCTS
US4740587A (en) 1985-07-18 1988-04-26 The Salk Institute For Biological Studies Inhibin and method of purifying same
US4721672A (en) 1985-08-28 1988-01-26 President And Fellows Of Harvard College CDNA and gene for human angiogenin (angiogenesis factor) and methods of expression
US4870163A (en) 1985-08-29 1989-09-26 New York Blood Center, Inc. Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4737578A (en) 1986-02-10 1988-04-12 The Salk Institute For Biological Studies Human inhibin
SE453566B (en) 1986-03-07 1988-02-15 Draco Ab POWDER INHALATOR DEVICE
US4767402A (en) 1986-07-08 1988-08-30 Massachusetts Institute Of Technology Ultrasound enhancement of transdermal drug delivery
NL8720442A (en) 1986-08-18 1989-04-03 Clinical Technologies Ass DELIVERY SYSTEMS FOR PHARMACOLOGICAL AGENTS.
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE3631229A1 (en) 1986-09-13 1988-03-24 Basf Ag MONOCLONAL ANTIBODIES AGAINST HUMAN TUMORNESCROSE FACTOR (TNF) AND THEIR USE
EP0832981A1 (en) 1987-02-17 1998-04-01 Pharming B.V. DNA sequences to target proteins to the mammary gland for efficient secretion
JP2647427B2 (en) 1987-04-24 1997-08-27 帝人株式会社 Detection method, monoclonal antibody, and detection kit for determining disease state of subject
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US4956288A (en) 1988-04-22 1990-09-11 Biogen, Inc. Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA
US5231166A (en) 1988-10-25 1993-07-27 Takeda Chemical Industries, Ltd. Endothelin
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5266491A (en) 1989-03-14 1993-11-30 Mochida Pharmaceutical Co., Ltd. DNA fragment and expression plasmid containing the DNA fragment
DE10399036I1 (en) 1989-08-07 2004-04-01 Peptide Technology Ltd Binding ligand for tumor necrosis factor.
US5580575A (en) 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5210026A (en) 1990-08-20 1993-05-11 American Cyanamid Company Human mk gene and method of expression
GB9022648D0 (en) 1990-10-18 1990-11-28 Charing Cross Sunley Research Polypeptide and its use
US5268465A (en) 1991-01-18 1993-12-07 The Johns Hopkins University Purification and molecular cloning of nitric oxide synthase
US5404871A (en) 1991-03-05 1995-04-11 Aradigm Delivery of aerosol medications for inspiration
EP0575545B1 (en) 1991-03-15 2003-05-21 Amgen Inc. Pegylation of polypeptides
US5834229A (en) 1991-05-24 1998-11-10 Genentech, Inc. Nucleic acids vectors and host cells encoding and expressing heregulin 2-α
IL101943A0 (en) 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
US5637481A (en) * 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
ES2141108T3 (en) 1991-07-02 2000-03-16 Inhale Inc METHOD AND DEVICE FOR PROVIDING DRUGS IN AEROSOL.
US5976835A (en) 1992-03-19 1999-11-02 The Rockefeller University Nucleic acids encoding receptor recognition factor Stat1α and Stat1β, and methods of use thereof
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
US5315000A (en) 1992-05-14 1994-05-24 Children's Hospital Medical Center Gene encoding for a L5/3 growth factor and its CDNA
WO1994006498A1 (en) 1992-09-23 1994-03-31 Fisons Plc Inhalation device
BR9307270A (en) 1992-10-19 1999-06-01 Dura Pharma Inc Dry powder inhaler
US5643252A (en) 1992-10-28 1997-07-01 Venisect, Inc. Laser perforator
US6143289A (en) 1992-12-09 2000-11-07 Indiana University Foundation Compositions of myeloid-cell-suppressive chemokines
US5849695A (en) 1993-01-13 1998-12-15 The Regents Of The University Of California Parathyroid hormone analogues useful for treatment of osteoporosis and disorders of calcium meatabolism in mammals
EP0680451B1 (en) 1993-01-19 1998-11-04 Glaxo Group Limited Aerosol dispenser and method of manufacture
EP0804561B1 (en) 1993-02-12 2009-12-30 The Board Of Trustees Of The Leland Stanford Junior University Regulated transcription of targeted genes and other biological events
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
US5814599A (en) 1995-08-04 1998-09-29 Massachusetts Insitiute Of Technology Transdermal delivery of encapsulated drugs
US5773569A (en) 1993-11-19 1998-06-30 Affymax Technologies N.V. Compounds and peptides that bind to the erythropoietin receptor
US5981478A (en) 1993-11-24 1999-11-09 La Jolla Cancer Research Foundation Integrin-binding peptides
US6190655B1 (en) 1993-12-03 2001-02-20 Immunex Corporation Methods of using Flt-3 ligand for exogenous gene transfer
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5880096A (en) 1994-02-02 1999-03-09 Affymax Technologies N.V. Peptides and compounds that bind to the IL-1 receptor
US5786331A (en) 1994-02-02 1998-07-28 Affymax Technologies N.V. Peptides and compounds that bind to the IL-1 receptor
US6174995B1 (en) 1994-08-23 2001-01-16 Haodong Li Human chemokines, CKβ4 and CKβ10/MCP-4
DE69527505D1 (en) 1994-11-11 2002-08-29 Noboru Kaneko MONOCLONAL ANTIBODY AGAINST ANTIANNEXIN-V, METHOD FOR THE PRODUCTION AND USE THEREOF
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US5767078A (en) 1995-06-07 1998-06-16 Johnson; Dana L. Agonist peptide dimers
US5817750A (en) 1995-08-28 1998-10-06 La Jolla Cancer Research Foundation Structural mimics of RGD-binding sites
US6284535B1 (en) 1995-09-07 2001-09-04 The Trustees Of Columbia University In The City Of New York Splice variants of the heregulin gene, nARIA and uses thereof
GB9526100D0 (en) 1995-12-20 1996-02-21 Intersurgical Ltd Nebulizer
CN1213974A (en) 1996-01-03 1999-04-14 葛兰素集团有限公司 Inhalation device
US5700774A (en) 1996-03-26 1997-12-23 Genetics Institute, Inc. Compositions comprising bone morphogenic proteins and truncated parathyroid hormone related peptide, and methods of inducing cartilage by administration of same
IL118003A0 (en) 1996-04-23 1996-08-04 Yeda Res & Dev Novel vip fragments and pharmaceutical compositions comprising them
US6271347B1 (en) 1996-04-26 2001-08-07 Merck & Co., Inc. Eosinophil eotaxin receptor
AU2978697A (en) 1996-06-07 1998-01-05 Takeda Chemical Industries Ltd. Novel peptide, process for the production of the same, and use of the same
DE69714698T2 (en) 1996-06-10 2002-12-05 Sucampo Ag Endothelin antagonists
US6126939A (en) 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
AU4159197A (en) 1996-09-04 1998-03-26 Warner-Lambert Company Biphenyl butyric acids and their derivatives as inhibitors of matrix metalloproteinases
US6030780A (en) 1996-10-15 2000-02-29 The Rockefeller University Purified Stat proteins and methods of purifying thereof
IL129851A0 (en) 1996-11-15 2000-02-29 Genentech Inc Purification of neurotrophins
DE69735383T2 (en) 1996-11-19 2007-02-15 Georgetown University Method for inhibiting HEREGULIN and its receptor and use for inhibiting cancer cells
US5948892A (en) 1996-12-16 1999-09-07 Amgen Inc. Analogs of macrophage stimulating protein
US5879681A (en) 1997-02-07 1999-03-09 Emisphere Technolgies Inc. Compounds and compositions for delivering active agents
US6136558A (en) 1997-02-10 2000-10-24 Genentech, Inc. Heregulin variants
US5921447A (en) 1997-02-13 1999-07-13 Glaxo Wellcome Inc. Flow-through metered aerosol dispensing apparatus and method of use thereof
IT1292017B1 (en) 1997-05-28 1999-01-25 Dompe Spa PHARMACEUTICAL COMPOSITIONS CONTAINING MACROPHAGE STIMULATING PROTEIN FOR THE TREATMENT OF NERVOUS SYSTEM PATHOLOGIES
IL120943A (en) 1997-05-29 2004-03-28 Univ Ben Gurion Transdermal delivery system
US6265535B1 (en) 1997-05-30 2001-07-24 The Trustees Of The University Of Pennsylvania Peptides and peptide analogues designed from binding sites of tumor necrosis factor receptor superfamily and their uses
AR016551A1 (en) 1997-07-30 2001-07-25 Smithkline Beecham Corp DERIVATIVES OF 2-OXINDOL, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM AND THE USE OF THE SAME FOR THE MANUFACTURE OF MEDICINES
US6180084B1 (en) * 1998-08-25 2001-01-30 The Burnham Institute NGR receptor and methods of identifying tumor homing molecules that home to angiogenic vasculature using same

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020012989A1 (en) * 1993-02-01 2002-01-31 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US5608035A (en) * 1994-02-02 1997-03-04 Affymax Technologies N.V. Peptides and compounds that bind to the IL-1 receptor
WO2000024782A2 (en) * 1998-10-23 2000-05-04 Amgen Inc. Modified peptides, comprising an fc domain, as therapeutic agents
WO2002046238A2 (en) * 2000-12-05 2002-06-13 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
WO2002046227A2 (en) * 2000-12-07 2002-06-13 Eli Lilly And Company Glp-1 fusion proteins
WO2003084477A2 (en) * 2002-03-29 2003-10-16 Centocor, Inc. Mammalian cdr mimetibodies, compositions, methods and uses

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
BES CEDRIC ET AL: "Efficient CD4 binding and immunosuppressive properties of the 13B8.2 monoclonal antibody are displayed by its CDR-H1-derived peptide CB1", FEBS LETTERS, vol. 508, no. 1, 9 November 2001 (2001-11-09), pages 67 - 74, XP004322279, ISSN: 0014-5793 *
CASARES SOFIA ET AL: "Foreign peptides expressed in engineered chimeric self molecules", BIOTECHNOLOGY AND GENETIC ENGINEERING REVIEWS INTERCEPT LTD. {A}, P. O. BOX 716, ANDOVER SP10 1YG, ENGLAND SERIES : BIOTECHNOLOGY AND GENETIC ENGINEERING REVIEWS (ISSN 0264-8725), 1998, pages 159 - 198, XP009069478, ISSN: 1-898298-54-8 *
HAYDEN M S ET AL: "Antibody engineering", CURRENT OPINION IN IMMUNOLOGY, CURRENT BIOLOGY LTD, vol. 9, no. 2, April 1997 (1997-04-01), pages 201 - 212, XP004327252, ISSN: 0952-7915 *
HAYDEN M S ET AL: "SINGLE-CHAIN MONO- AND BISPECIFIC ANTIBODY DERIVATIVES WITH NOVEL BIOLOGICAL PROPERTIES AND ANTITUMOUR ACTIVITY FROM A COS CELL TRANSIENT EXPRESSION SYSTEM", THERAPEUTIC IMMUNOLOGY, BLACKWELL SCIENTIFIC PUBL. LONDON, GB, vol. 1, no. 1, January 1994 (1994-01-01), pages 3 - 15, XP009023719, ISSN: 0967-0149 *
HUFTON-SE ET AL: "Development and application of cytotoxic T lymphocyte-associated antigen 4 as a protein scaffold for the generation of novel binding ligands", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 475, no. 3, 23 June 2000 (2000-06-23), pages 225 - 231, XP004337267, ISSN: 0014-5793 *
IGARASHI T ET AL: "Structure of a mouse immunoglobulin G that lacks the entire CH1 domain: protein sequencing and small-angle X-ray scattering studies.", BIOCHEMISTRY. 19 JUN 1990, vol. 29, no. 24, 19 June 1990 (1990-06-19), pages 5727 - 5733, XP002389674, ISSN: 0006-2960 *
JACOBIN MARIE-JOSEE ET AL: "Human IgG monoclonal anti-alphaIIbbeta3-binding fragments derived from immunized donors using phage display.", JOURNAL OF IMMUNOLOGY, vol. 168, no. 4, 15 February 2002 (2002-02-15), pages 2035 - 2045, XP002389673, ISSN: 0022-1767 *
LAMBERT MIREILLE ET AL: "Immobilized dimers of N-cadherin-Fc chimera mimic cadherin-mediated cell contact formation: Contribution of both outside-in and inside-out signals", JOURNAL OF CELL SCIENCE, vol. 113, no. 12, June 2000 (2000-06-01), pages 2207 - 2219, XP002389675, ISSN: 0021-9533 *
LIVNAH O ET AL: "FUNCTIONAL MIMICRY OF A PROTEIN HORMONE BY A PEPTIDE AGONIST: THE EPO RECEPTOR COMPLEX AT 2.8 AA", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, WASHINGTON, DC; US, vol. 273, 26 July 1996 (1996-07-26), pages 464 - 471, XP002021035, ISSN: 0036-8075, DOI: 10.1126/SCIENCE.273.5274.464 *
MONNET CELINE ET AL: "Synthetic peptides derived from the variable regions of an anti-CD4 monoclonal antibody bind to CD4 and inhibit HIV-1 promoter activation in virus-infected cells", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, no. 6, 5 February 1999 (1999-02-05), pages 3789 - 3796, XP002283342, ISSN: 0021-9258 *
SAGOT MARIE-ASTRID ET AL: "A monoclonal antibody directed against the neurokinin-1 receptor contains a peptide sequence with similar hydropathy and functional properties to substance P, the natural ligand for the receptor", MOLECULAR IMMUNOLOGY, vol. 37, no. 8, June 2000 (2000-06-01), pages 423 - 433, XP002389672, ISSN: 0161-5890 *
See also references of WO2004002417A2 *
WELLS J A: "HORMONE MIMICRY", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, WASHINGTON, DC; US, vol. 273, 26 July 1996 (1996-07-26), pages 449/450, XP000999487, ISSN: 0036-8075, DOI: 10.1126/SCIENCE.273.5274.449 *
WRIGHTON N C ET AL: "Small peptides as potent mimetics of the protein hormone erythropoietin", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, WASHINGTON, DC; US, no. 273, 1 July 1996 (1996-07-01), pages 458 - 463, XP002074894, ISSN: 0036-8075, DOI: 10.1126/SCIENCE.273.5274.458 *

Also Published As

Publication number Publication date
AU2003280130A1 (en) 2004-01-19
WO2004002417A3 (en) 2004-11-04
EP1545608A2 (en) 2005-06-29
CA2490409A1 (en) 2004-01-08
JP2006504406A (en) 2006-02-09
WO2004002417A2 (en) 2004-01-08
CN1735433A (en) 2006-02-15
AU2003280130B2 (en) 2009-06-11

Similar Documents

Publication Publication Date Title
EP1545608A4 (en) Mammalian ch1 deleted mimetibodies, compositions, methods and uses
WO2004002424A8 (en) Mammalian epo mimetic ch1 deleted mimetibodies, compositions, methods and uses
AU2003222069A8 (en) Mammalian cdr mimetibodies, compositions, methods and uses
EP1572079A3 (en) Mammalian cdr mimetibodies, compositions, methods and uses
EP1542699A4 (en) Compounds, compositions, and methods employing same
AU2003251858A1 (en) Microbubble compositions, and methods for preparing and using same
AU2003262747A8 (en) Compounds, compositions, and methods
EP1503993A4 (en) Compounds, methods and compositions
AU2003236527A8 (en) Compounds, compositions, and methods
AU2003265242A8 (en) Compounds, compositions, and methods
HK1070656A1 (en) Compounds, compositions, and methods
AU2003270015A8 (en) Compounds, compositions, and methods
AU2003299612A8 (en) Compounds, compositions and methods
IL167936A0 (en) Compounds, compositions,and methods
AU2003286474A8 (en) Compositions, solutions, and methods used for transplantation
AU2003290507A8 (en) Compounds, compositions and methods
EP1711527A4 (en) Hla-dr-specific antibodies, compositions and methods
AU2003277079A8 (en) Compounds, compositions, and methods
AU2003237332A8 (en) Anti-relp fusion antibodies, compositions, methods and uses
AU2003293765A1 (en) Novel skin lightening agents, compositions and methods
AU2003267169A8 (en) Compounds, compositions and methods
AU2003300031A8 (en) Compounds, compositions, and methods
AU2002952442A0 (en) Probiotic Compositions, Combinations and Related Methods
AU2003239594A8 (en) Bryostatins, bryopyrans and polyketides: compositions and methods
AU2002323480A1 (en) Oxadiazolyl-phenoxyalkylisoxazoles, compositions thereof and methods for their use as anti-picornaviral agents

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050127

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20060810

17Q First examination report despatched

Effective date: 20080225

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CENTOCOR ORTHO BIOTECH INC.

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: JANSSEN BIOTECH, INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120508